Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu shot in adults aged 50 years and older in a late-stage study. Shares of the company were up 5.

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a standard flu shot, the company announced this week.

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to the Centers for Disease Control and Prevention.